PHIO logo

Phio Pharmaceuticals Corp.

PHIO
Healthcare|Biotechnology|US
$0.80
+0.00 (+0.16%)
DCF Value
$3.45
Tangible Book / Share
$0.74
Cash / Share
$0.91
Next Earnings Report
Mar 4, 2027
EPS est. -$0.39
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Apr 8, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (1)

Dec 2026
Est. completion
P1HNSCC
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
NCT05902520n=18

Recent Press Releases

Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
Nov 6, 2026 · Newsfile Corp
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
Nov 5, 2026 · Newsfile Corp
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Oct 19, 2026 · Newsfile Corp
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Oct 13, 2026 · Newsfile Corp
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Oct 6, 2026 · Newsfile Corp
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
Oct 5, 2026 · Newsfile Corp
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Sep 23, 2026 · Newsfile Corp
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
Sep 14, 2026 · Newsfile Corp
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 11, 2026 · Newsfile Corp
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
Aug 11, 2026 · Newsfile Corp

SEC Filings (94)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 13, 20268-KMaterial eventDocumentIndex
Sep 28, 2026S-8Employee stock planDocumentIndex
Sep 28, 20268-KMaterial eventDocumentIndex
Sep 14, 20268-KMaterial eventDocumentIndex
Aug 14, 2026ARSAnnual report to holdersDocumentIndex
Aug 14, 2026DEFA14AProxy / shareholder voteDocumentIndex
Aug 14, 2026DEF 14AProxy / shareholder voteDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Jul 21, 20268-KMaterial eventDocumentIndex
May 7, 202610-QQuarterly reportDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
Apr 8, 20268-KMaterial eventDocumentIndex
Apr 8, 2026424B5Offering prospectusDocumentIndex
Mar 30, 20268-KMaterial eventDocumentIndex
Mar 5, 202610-KAnnual reportDocumentIndex
Mar 5, 20268-KMaterial eventDocumentIndex
Feb 18, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 10, 20268-KMaterial eventDocumentIndex
Jan 20, 20268-KMaterial eventDocumentIndex
Dec 23, 20258-KMaterial eventDocumentIndex
Dec 11, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Dec 4, 2025424B3Offering prospectusDocumentIndex
Dec 3, 2025EFFECTDocumentIndex
Nov 25, 20258-KMaterial eventDocumentIndex
Nov 24, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 20, 2025S-3Shelf registrationDocumentIndex
Nov 13, 202510-QQuarterly reportDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Nov 12, 2025DDocumentIndex
Nov 12, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 10, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 7, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 6, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 6, 20258-KMaterial eventDocumentIndex
Nov 3, 20258-KMaterial eventDocumentIndex